Contents

MOD was conceived of by several members of their board of directors and advisory board in 2016. Thanks
to a partnership with the Communication Systems Group at the University of Zurich, a small team of engineers
was assembled to compete in the 2016 Kickstart Accelerator. After winning the Future Emerging Technology
Vertical, the company was formed as an AG in Switzerland and began conducting pilot projects in Europe all
the way to the Middle East. The modum team has grown from 5 to 15 in the 2017 calendar year. Their token
sale, held in September 2017, saw 17 366 200 sold to the public.

The modum system is designed with a clear design focus on automation and security. It consists of multiple
hardware and software components.
• A pharma-qualified temperature logger, which monitors temperature during transport. It communicates
wirelessly to a mobile application via BLE (Bluetooth Low Energy) or NFC (Near Field Communication).
• A desktop dashboard enables the preparation (e.g. setting alarm criteria) and tracking of shipments, data
visualization and analytics, and can be used to perform statistical calculations on historical data, e.g. shipment
comparison, with export functionality.
• The mobile application can be used to pair the temperature loggers with the respective shipments, initialize
shipments and visualize the recorded data.
• The back end is for data retrieval, evaluation, verification and storage. It also runs an ethereum full node
executing the respective smart contract code. The front end (dashboard, temperature logger and mobile
application) communicates with back-end’s HTTPS server via RestAPI/JSON.

The modum temperature logger has been developed with an operating temperature range of -10 C to 70 C,
with measurement intervals between 1 second to 1 week. The sensor will have the capacity to store 50,000
measurements with a 6 week active/ 1 year passive battery life.

The regulations outlined by the European Commission for the Good Distribution Practice of medicinal products
for human use (GDP 2013/C 343/01) were published on November 5, 2013. Chapter nine of this regulation
requires proof that shipped medicines have not been exposed to conditions, particularly temperatures, that
may compromise their quality. These regulations are now enforceable across Europe.